Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man - PubMed (original) (raw)

Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man

T Lundåsen et al. J Intern Med. 2006 Dec.

Free article

Erratum in

J Intern Med. 2008 Apr;263(4):459

Abstract

Bile acids (BAs) traversing the enterohepatic circulation exert several important metabolic effects. Their hepatic synthesis, controlled by the enzyme cholesterol 7alpha-hydroxylase (CYP7A1), has a unique diurnal variation in man. Here we provide evidence that the transintestinal flux of BAs regulates serum levels of intestinal fibroblast growth factor 19 (FGF19) that in turn modulate BA production in human liver. Basal FGF19 levels varied by 10-fold in normal subjects, and were reduced following treatment with a BA-binding resin and increased upon feeding the BA chenodeoxycholic acid. Serum FGF19 levels exhibited a pronounced diurnal rhythm with peaks occurring 90-120 min after the postprandial rise in serum BAs. The FGF19 peaks in turn preceded the declining phase of BA synthesis. The diurnal rhythm of serum FGF19 was abolished upon fasting. We conclude that, in humans, circulating FGF19 has a diurnal rhythm controlled by the transintestinal BA flux, and that FGF19 modulates hepatic BA synthesis. Through its systemic effects, circulating FGF19 may also mediate other known BA-dependent effects on lipid and carbohydrate metabolism.

PubMed Disclaimer

Cited by

An Inverse Correlation of Serum Fibroblast Growth Factor 19 with Abdominal Pain and Inflammatory Markers in Patients with Ulcerative Colitis.
Panek-Jeziorna M, Mulak A. Panek-Jeziorna M, et al. Gastroenterol Res Pract. 2020 May 29;2020:2389312. doi: 10.1155/2020/2389312. eCollection 2020. Gastroenterol Res Pract. 2020. PMID: 32565779 Free PMC article.
Diurnal variation in cholesterol 7α-hydroxylase activity is determined by the -203A>C polymorphism of the CYP7A1 gene.
Vlachova M, Blahova T, Lanska V, Leníček M, Pitha J, Vítek L, Kovar J. Vlachova M, et al. Croat Med J. 2016 Apr 23;57(2):111-7. doi: 10.3325/cmj.2016.57.111. Croat Med J. 2016. PMID: 27106353 Free PMC article.
Recent Advances in the Digestive, Metabolic and Therapeutic Effects of Farnesoid X Receptor and Fibroblast Growth Factor 19: From Cholesterol to Bile Acid Signaling.
Di Ciaula A, Bonfrate L, Baj J, Khalil M, Garruti G, Stellaard F, Wang HH, Wang DQ, Portincasa P. Di Ciaula A, et al. Nutrients. 2022 Nov 22;14(23):4950. doi: 10.3390/nu14234950. Nutrients. 2022. PMID: 36500979 Free PMC article. Review.
Sulfated glycosaminoglycans are required for specific and sensitive fibroblast growth factor (FGF) 19 signaling via FGF receptor 4 and betaKlotho.
Nakamura M, Uehara Y, Asada M, Honda E, Nagai N, Kimata K, Suzuki M, Imamura T. Nakamura M, et al. J Biol Chem. 2011 Jul 29;286(30):26418-23. doi: 10.1074/jbc.M111.251140. Epub 2011 Jun 8. J Biol Chem. 2011. PMID: 21653700 Free PMC article.
AhR and SHP regulate phosphatidylcholine and S-adenosylmethionine levels in the one-carbon cycle.
Kim YC, Seok S, Byun S, Kong B, Zhang Y, Guo G, Xie W, Ma J, Kemper B, Kemper JK. Kim YC, et al. Nat Commun. 2018 Feb 7;9(1):540. doi: 10.1038/s41467-018-03060-y. Nat Commun. 2018. PMID: 29416063 Free PMC article.

Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man - PubMed (original) (raw)